NCT03739970Unknown不适用
A Clinical Trial of Silk Peptide for the Evaluation of Efficacy on Immune Function Enhancement
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 110
- 试验地点
- 2
- 主要终点
- NK(Natural killer) cell activity
研究概览
简要总结
This study is a 8-week, randomized, double-blind, placebo-controlled clinical trial of Silk Peptide for the evaluation of efficacy on immune function enhancement.
详细描述
This study will evaluate Silk Peptide's efficacy on immune function in healthy volunteers who white blood cells count is in between 4000/㎕ and 8000/㎕ by assessing improvements in certain immune indices (i.e. NK cell activity, IFN-γ, TNF-α, IL-1β, 2, 12, IgG1, IgG2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult male and female volunteers over 50 years
- •Screening result for WBC counts in between 4,000 cells/ul and 8,000 cells/ul
- •Volunteers who have agreed to participate in the study and provided a written content by him/herself or through its legal representative
排除标准
- •Those with a history of drug and clinically significant hypersensitivity reactions
- •Those with thyroid or pituitary disease
- •Those with acute severe cardiovascular disease such as heart failure, myocardial infarction, and stroke
- •Those with immune system disease or severe liver failure, kidney failure or history
- •Those with a history of systemic diseases such as malignancy, lung disease, leukemia, collagenosis, multiple sclerosis, allergic skin disease and other autoimmune diseases
- •Those with a BMI of less than 18.5 kg/m2 at screening
- •Those diagnosed with diabetes
- •Those with a history of gastrointestinal disorders (ex. Crohn's disease) or gastrointestinal surgery (excluding simple appendectomy or hernia surgery) that may affect the absorption of clinical trial products
- •Those who have consumed medicines, healthy functional foods within 2 weeks before screening or are currently consuming health supplements that can affect immune function. (For health functional foods, they can participate through 1 week before the first intake day.)
- •Those who have received antipsychotic medication within 2 months before screening
- •Those with a alcoholism or history of substance abuse
- •Those who participated in other clinical trials within 2 months before screening
- •Those who are pregnant, breastfeeding
- •Fertile women who do not accept the appropriate method of contraception (except for women who have undergone sterilization operation)
- •Those who are deemed inappropriate by the researcher
研究组 & 干预措施
Investigational Group- Silk Peptide
Experimental
- Ingredient: Silk Peptide
- Type: Yellow granule stick
- Weight: Silk Peptide 9g/day
- Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)
- Duration of use: 8 weeks
干预措施: Investigational Product (Silk Peptide) (Dietary Supplement)
Control Group - Placebo Product
Placebo Comparator
- Ingredient: Microcrystalline Cellulose
- Type: Yellow granule stick
- Weight: Silk Peptide 0g/day
- Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)
- Duration of use: 8 weeks
干预措施: Control Group - Placebo Product (Dietary Supplement)
结局指标
主要结局
NK(Natural killer) cell activity
时间窗: 0 week, 8 week
Changes of NK(Natural killer) cell activity were before and after the intervention
次要结局
- TNF-α(0 week, 8 week)
- IgG1(0 week, 8 week)
- IgG2(0 week, 8 week)
- IFN-γ(0 week, 8 week)
- IL-1β(0 week, 8 week)
- IL-2(0 week, 8 week)
- IL-6(0 week, 8 week)
- IL-12(0 week, 8 week)
研究者
Jong Ho Lee
Professor, Principal Investigator
Yonsei University
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Effects of Bifidobacterium Longum 1714® in a Population With Low MoodLow MoodDepressive SymptomsNCT04925440PrecisionBiotics Group Ltd.168
已完成
1 期
SB17170 Phase1 Trial in Healthy VolunteerSafety IssuesTolerabilityPharmacokineticsPharmacodynamicsNCT05795192SPARK Biopharma64
终止
1 期
Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male SubjectsHealthy ParticipantsNCT03402178Eisai Co., Ltd.118
已完成
2 期
Sitagliptin for Reducing Inflammation and Immune ActivationHIV-1 InfectionNCT02513771Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections90
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With StatinsLDL CholesterolHypercholesterolemiaNCT01859455Novartis Pharmaceuticals25